Skip to main content
HCPCS Q5167 · Level II · Part B drug

Q5167: denosumab-qbde (Enoby, Xtrenbo), HCPCS Level II drug code

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: ASP payment limits: October 2026 (effective October 1, 2026); NCCI MUE tables: 2026 Q4 (effective October 1, 2026); NCCI PTP edits: v323r0 (2026 Q4) (effective October 1, 2026); OPPS Addendum B: October 2026 (effective October 1, 2026); ASC Addendum BB (covered ancillary services): October 2026 (effective October 1, 2026). Next CMS release: January 1, 2027 (quarterly update).

Key facts for Q5167

Billing unit
1 MG
Inj, denosumab-qbde, 1 mg
ASP payment limit
$7.681
October 2026
Practitioner MUE
none published
CMS publishes no MUE for this code
OPPS status
SI K
APC 0949
NCCI exposure
no PTP pairs
Coverage articles
1
5 states

TL;DR

HCPCS Q5167 is the Level II code for Injection, denosumab-qbde (enoby/xtrenbo), biosimilar, 1 mg, billed per 1 MG. The Medicare Part B ASP payment limit for October 2026 is $7.681 per billing unit. Under OPPS it carries status indicator K in APC 0949. As a biosimilar it has its own code and ASP; the reference product cannot be billed under this code, and the JZ or JW modifier rules for discarded amounts apply per single-dose vial. With a 1 mg billing unit, a single administration can be hundreds of units; the unit count on the claim must equal the milligrams given, and rounding rules for partial units follow the contractor's guidance. Other HCPCS codes whose descriptor names denosumab: Q5162 (biosimilar denosumab-nxxp (Bildyos/Bilprevda) from Organon LLC); Q5161 (biosimilar denosumab-kyqq (Aukelso/Bosaya) from Biocon Biologics Inc); Q5158 (biosimilar denosumab-bnht (Bomyntra/Conexxence) from Fresenius Kabi USA, LLC); Q5157 (biosimilar denosumab-bmwo (Stoboclo/Osenvelt) from Celltrion USA, Inc); Q5136 (biosimilar denosumab-bbdz (Jubbonti/Wyost) from Sandoz Inc); J0897 (non-biosimilar denosumab from Amgen Inc). The ASP crosswalk maps 2 NDCs to it, sold as Enoby, Xtrenbo by Hikma Pharmaceuticals USA Inc. 1 Medicare coverage article lists the code across 5 states, including A52399.

Medicare Part B payment limit (ASP)

CMS sets the Part B payment limit for Q5167 at $7.681 per 1 MG for October 2026, derived from manufacturer average sales price plus 6%. Beneficiary coinsurance is 20%.

ASP payment limits for Q5167
QuarterPayment limitPerCoinsurance
October 2026$7.6811 MG20%
July 2026n/a1 MG—
CMS note: Added October 2026; 8% of reference add-on applied

NDC to HCPCS billing-unit conversion

The October 2026 ASP crosswalk maps 2 NDCs from 1 labeler to Q5167. Report the NDC in the claim's drug segment and bill the number of Q5167 units that equals the quantity administered divided by 1 MG; the last column gives units per full package.

NDCs that crosswalk to Q5167
NDCDrug nameLabelerPackage sizeBilling units / package
00143-9165-01EnobyHikma Pharmaceuticals USA Inc.1 × 160
00143-9166-01XtrenboHikma Pharmaceuticals USA Inc.1.7 × 1120

Medically Unlikely Edits (MUE)

CMS does not publish an MUE for Q5167 in the 2026 Q4 tables. Some MUE values are confidential and applied without publication, so unit limits can still deny; document the dose and the units calculation on every claim.

MUE for Q5167 in every setting opens the lookup with this code filled in, next to any other code on the same claim.

NCCI edits and add-on relationships

No active practitioner PTP pair lists Q5167 as a column-1 or column-2 code in v323r0. Drug supply codes are rarely bundled; the administration codes billed with them are where PTP edits usually apply.

The counts above are exposure, not answers for a specific claim. Check Q5167 against another code to see whether a given pair bundles, which code is paid and whether a modifier can separate them.

Q5167 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.

Medicare coverage articles

1 current Medicare Administrative Contractor article lists Q5167 in their HCPCS tables, covering 5 states. Each article carries the covered and non-covered ICD-10 codes that medical-necessity denials (CARC 50) are adjudicated against.

Billing and Coding Articles listing Q5167
ArticleTitleContractor(s)StatesRelated LCD
A52399Billing and Coding: Denosumab (Prolia®, Xgeva®, Jubbonti®) and biosimilarsWellpoint FederalCT IL MN NY WIL33394

Diagnoses Medicare contractors cover for Q5167

One billing and coding article attaches a covered diagnosis list to Q5167: 434 distinct ICD-10-CM codes in all. The 15 below come first by how many of those articles cover them, then in the contractor's own order. The claim line is checked against the list of the contractor that processes it, and a diagnosis outside that list is denied as not medically necessary (CARC 50).

First 15 covered ICD-10-CM codes for Q5167
ICD-10-CMDescription (FY2027)Articles covering
C33Malignant neoplasm of trachea1 of 1
C34.00Malignant neoplasm of unspecified main bronchus1 of 1
C34.01Malignant neoplasm of right main bronchus1 of 1
C34.02Malignant neoplasm of left main bronchus1 of 1
C34.10Malignant neoplasm of upper lobe, unspecified bronchus or lung1 of 1
C34.11Malignant neoplasm of upper lobe, right bronchus or lung1 of 1
C34.12Malignant neoplasm of upper lobe, left bronchus or lung1 of 1
C34.2Malignant neoplasm of middle lobe, bronchus or lung1 of 1
C34.30Malignant neoplasm of lower lobe, unspecified bronchus or lung1 of 1
C34.31Malignant neoplasm of lower lobe, right bronchus or lung1 of 1
C34.32Malignant neoplasm of lower lobe, left bronchus or lung1 of 1
C34.80Malignant neoplasm of overlapping sites of unspecified bronchus and lung1 of 1
C34.81Malignant neoplasm of overlapping sites of right bronchus and lung1 of 1
C34.82Malignant neoplasm of overlapping sites of left bronchus and lung1 of 1
C34.90Malignant neoplasm of unspecified part of unspecified bronchus or lung1 of 1
419 more codes are in the full lists linked below.

Contractors split an article's diagnoses into numbered groups and say in each group's instructions which procedure codes it supports. Only the groups that apply to Q5167 are counted here: a group whose instructions name Q5167, together with any unnamed groups directly after it, read as continuations of those instructions. The full list opens on the policy page with every group, the non-covered codes and the instructions.

Covered diagnosis lists that apply to Q5167, by article
ArticleContractorGroups that applyCovered codes for Q5167Full list
A52399Wellpoint Federalgroups 1 and 2 apply to Q5167434On LCD L33394

Local coverage policies that list Q5167

1 active Local Coverage Determination lists Q5167 in the policy or in its billing and coding article. Each applies only in its contractor's jurisdiction; check the one for the state where the drug is administered.

Hospital outpatient (OPPS) status

In the October 2026 OPPS Addendum B, Q5167 carries status indicator K and is assigned to APC 0949, with a published national unadjusted payment of $7.68. Status K means the drug is paid separately under OPPS at the ASP-based rate rather than packaged into the procedure.

Ambulatory surgical center (ASC) payment

In the October 2026 ASC Addendum BB (covered ancillary services), Q5167 carries payment indicator K2, which CMS defines as "Drugs, biologicals, and radiopharmaceuticals paid separately when provided integral to a surgical procedure on ASC list; payment based on OPPS rate". The national ASC payment is $7.68 per 1 MG, paid only when the drug is furnished integral to a covered surgical procedure.

Common denials for Q5167 and how to prevent them

NDC missing, invalid or not matched to the HCPCS code

units billed exceed the MUE for the date of service

diagnosis not covered by the applicable coverage article or LCD

For teams evaluating QuickIntell software

Evaluate a coding workflow for Q5167

Use the unit, NDC and edit questions in this reference to scope a QuickCode evaluation for qualified coder review, documentation clarification and the billing handoff. Confirm supported code sets, data inputs and reviewer responsibilities; the reference tables do not establish that a particular automated check or payer integration is available.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — HCPCS Q5167

What does HCPCS code Q5167 describe?

Q5167 is defined by CMS as "Injection, denosumab-qbde (enoby/xtrenbo), biosimilar, 1 mg". Each billing unit represents 1 MG, so the units reported on the claim must equal the dose administered divided by that unit.

Is Q5167 a CPT code?

No. Q5167 is a HCPCS Level II code, the letter-plus-four-digit set CMS maintains for drugs such as denosumab-qbde; CPT codes are five-character codes maintained by the AMA. On a Part B claim Q5167 reports the drug itself in 1 mg units, and the administration is billed on its own line.

What is the Medicare reimbursement for Q5167 in October 2026?

The ASP-based payment limit is $7.681 per 1 MG, with 20% beneficiary coinsurance. Commercial payers use their own fee schedules.

Which NDCs map to Q5167?

The October 2026 ASP crosswalk lists 2 NDCs from 1 labeler: Enoby (Hikma Pharmaceuticals USA Inc.); Xtrenbo (Hikma Pharmaceuticals USA Inc.). For example NDC 00143-9165-01 (package size 1) equals 60 billing units of Q5167.

Does Q5167 have NCCI bundling edits?

No active practitioner PTP pairs list Q5167 as a column-1 or column-2 code in the v323r0 release.

Q5167 vs Q5162: what is the difference?

Both are HCPCS Level II codes whose descriptor names denosumab. What sets Q5162 apart: biosimilar denosumab-nxxp (Bildyos/Bilprevda) from Organon LLC. Q5167 is billed per 1 mg, limit $7.681; Q5162 is billed per 1 mg, limit $15.336. Report the code whose descriptor matches the product and setting in the record.

Q5167 vs Q5161: what is the difference?

Both are HCPCS Level II codes whose descriptor names denosumab. What sets Q5161 apart: biosimilar denosumab-kyqq (Aukelso/Bosaya) from Biocon Biologics Inc. Q5167 is billed per 1 mg, limit $7.681; Q5161 is billed per 1 mg, limit $27.509. Report the code whose descriptor matches the product and setting in the record.

Which Medicare coverage articles mention Q5167?

1 current Billing and Coding Article in the Medicare Coverage Database lists Q5167, covering 5 states: A52399 (Billing and Coding: Denosumab (Prolia®, Xgeva®, Jubbonti®) and biosimilars).

What diagnosis codes support Q5167?

One Medicare billing and coding article lists 434 covered ICD-10-CM codes for Q5167, for example C33 (Malignant neoplasm of trachea); C34.00 (Malignant neoplasm of unspecified main bronchus); C34.01 (Malignant neoplasm of right main bronchus); C34.02 (Malignant neoplasm of left main bronchus); C34.10 (Malignant neoplasm of upper lobe, unspecified bronchus or lung). Each contractor's list applies only in its own jurisdiction, so the claim must carry a code from the article of the contractor that processes it.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B, ASC Addendum BB and the Medicare Coverage Database. Payment limits and rates are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.